Avstera Therapeutics is an oncology-focused biotech company headquartered in the Philadelphia area dedicated to address the large disease burden and significant unmet need of advanced cancer patients. With a focus on foundational tumor biology science, Avstera leverages cutting edge approaches to tackle key immunological challenges seen in the tumor microenvironment, such as the modulation of immunosuppressive macrophages. Avstera's lead program is an orally bioavailable, highly selective HDAC6i which is in Phase I.